Research
Hormonal
Enobosarm increases lean body mass but fails to deliver consistent, clinically meaningful functional gains (e.g., stair-climb power) in cancer cachexia patients, leading to regulatory rejection.
Enobosarm was tested for cancer cachexia and successfully increased muscle mass, but it did not improve physical function enough to gain FDA approval. This highlights that muscle size alone does not guarantee functional improvement in sick populations.
GoodQualifiesHIGH confidence
It was a major setback when it became clear that both programmes increased LBM but failed to deliver consistent, clinically meaningful functional gains, and thus no approval followed.
Why this rating
Based on Phase III trials (POWER-1 and POWER-2) which are peer-reviewed and robust, though the outcome was negative for functional endpoints.
Source
Enobosarm in Muscle Wasting
Stephan von Haehling · JCSM Communications · 2026
DOI 10.1002/rco2.70027
narrative_reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →